Cargando…

Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptibleEscherichia colibloodstream infection

BACKGROUND: Cefiderocol, ceftazidime-avibactam, ceftolozane-tazobactam, intravenous fosfomycin and plazomicin represent potential carbapenem sparing agents for extended-spectrum-beta-lactamase or AmpC beta-lactamase producing Escherichia coli infection. However, available data is limited in predicti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Ouli, Cisera, Kathryn, Taylor, Lucy, Hughes, Carly, Rogers, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708213/ https://www.ncbi.nlm.nih.gov/pubmed/33256752 http://dx.doi.org/10.1186/s12941-020-00400-z

Ejemplares similares

Treatment of Piperacillin-Tazobactam–Nonsusceptible/Ceftriaxone-Susceptible Infections With Carbapenem Versus Carbapenem-Sparing Antimicrobials
por: Cao, John, et al.
Publicado: (2023)

2290. Carbapenem vs. Piperacillin–tazobactam Definitive Therapy for Patients with Bloodstream Infections Due to Ceftriaxone Not Susceptible Escherichia coli or Klebsiella species
por: MacVane, Shawn H, et al.
Publicado: (2019)

215. Shorter vs. Longer Duration of Treatment in Patients with Ceftriaxone-resistant and Ceftriaxone-susceptible Escherichia coli Bloodstream Infections
por: Mackow, Natalie A, et al.
Publicado: (2023)

Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible
por: Baker, Thomas M, et al.
Publicado: (2018)

646. Adapting the modified Carbapenem Inactivation Method to assess for possible beta-lactamase mediated resistance in Piperacillin-Tazobactam resistant/ Ceftriaxone susceptible Escherichia. coli and Klebsiella pneumoniae
por: Lawandi, Alexander, et al.
Publicado: (2020)

CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales
por: Rodríguez-Baño, Jesús, et al.
Publicado: (2021)

305. Prevalence of Ceftriaxone Susceptible, Piperacillin-tazobactam Non-susceptible Escherichia coli Bacteremia in Patients with Hematologic Malignancy
por: Spitznogle, Sarah L, et al.
Publicado: (2020)

PRO: Carbapenems should be used for ALL infections caused by ceftriaxone-resistant Enterobacterales
por: Paterson, David L, et al.
Publicado: (2021)

Evaluation of Ceftriaxone Utilization at Multicenter Study
por: Lee, Hyuck, et al.
Publicado: (2009)

Carbapenem-Resistant but Cephalosporin-Susceptible Pseudomonas aeruginosa in Urinary Tract Infections: Opportunity for Colistin Sparing
por: Gajdács, Márió
Publicado: (2020)

Identification of Multiple Low-Level Resistance Determinants and Coselection of Motility Impairment upon Sub-MIC Ceftriaxone Exposure in Escherichia coli
por: Ching, Carly, et al.
Publicado: (2021)

Neisseria gonorrhoeae Aggregation Reduces Its Ceftriaxone Susceptibility
por: Wang, Liang-Chun, et al.
Publicado: (2018)

Carbapenem-Sparing Strategies for ESBL Producers: When and How
por: Karaiskos, Ilias, et al.
Publicado: (2020)

Unusual carbapenem resistant but ceftriaxone and cefepime susceptible Klebsiella oxytoca isolated from a blood culture: Case report and whole-genome sequencing investigation
por: Yang, Shangxin, et al.
Publicado: (2017)

Role of Chromosome- and/or Plasmid-Located bla(NDM) on the Carbapenem Resistance and the Gene Stability in Escherichia coli
por: Sakamoto, Noriko, et al.
Publicado: (2022)

Cinnamaldehyde Restores Ceftriaxone Susceptibility against Multidrug-Resistant Salmonella
por: Yin, Lizi, et al.
Publicado: (2023)

Carbapenem vs. Piperacillin-tazobactam for the Treatment of Ceftriaxone-Resistant Gram-Negative Bacteremia: Matched Cohorts by Propensity Score
por: Rajagopal, Sumanth, et al.
Publicado: (2017)

1452. Is Carbapenem-Sparing Therapy as Effective as Carbapenems Against Extended-Spectrum β-Lactamase Producing Enterobacteriaceae in UTI?
por: Hyun, Jonghoon, et al.
Publicado: (2019)

New Clinical Strain of Neisseria gonorrhoeae with Decreased Susceptibility to Ceftriaxone, Japan
por: Deguchi, Takashi, et al.
Publicado: (2016)

Conjunctivitis Caused by a Strain of Neisseria gonorrhoeae That Was Less Susceptible to Ceftriaxone
por: Iwata, Akira, et al.
Publicado: (2017)

Azithromycin Resistance and Decreased Ceftriaxone Susceptibility in Neisseria gonorrhoeae, Hawaii, USA
por: Papp, John R., et al.
Publicado: (2017)

A Case of Bacteremia and Meningitis Associated with Piperacillin-Tazobactam Nonsusceptible, Ceftriaxone Susceptible Escherichia coli during Strongyloides Hyperinfection in an Immunocompromised Host
por: Dahal, Santosh, et al.
Publicado: (2017)

1228. Outcomes Associated with Empiric Cefepime or Meropenem for Bloodstream Infections Caused by Ceftriaxone-Resistant, Cefepime-Susceptible Escherichia coli and Klebsiella pneumoniae
por: Frescas, Brian E, et al.
Publicado: (2021)

More mutation accumulation in Neisseria gonorrhoeae (NG) with susceptibility than that in NG with decreased susceptibility to ceftriaxone
por: Liang, Jing-Yao, et al.
Publicado: (2020)

Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic
por: Lupia, Tommaso, et al.
Publicado: (2022)

Escherichia coli Exopolysaccharides Induced by Ceftriaxone Regulated Human Gut Microbiota in vitro
por: Li, Baiyuan, et al.
Publicado: (2021)

Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for Commonly Utilized Parenteral Agents against Methicillin-Susceptible Staphylococcus aureus: Focus on Ceftriaxone Discordance between Predictive Susceptibility and in Vivo Exposures
por: Kang, Nayon, et al.
Publicado: (2015)

Antiamoebic Properties of Ceftriaxone and Zinc-Oxide–Cyclodextrin-Conjugated Ceftriaxone
por: Makhlouf, Zinb, et al.
Publicado: (2022)

1809. Treatment Outcomes in Piperacillin-tazobactam Non-susceptible (TZP-NS)/Ceftriaxone Susceptible (CRO-S) Infections
por: Dubrovskaya, Yanina, et al.
Publicado: (2022)

Ceftriaxone for the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia: A Case Series
por: Lowe, Rachel Amanda, et al.
Publicado: (2017)

266. Ceftriaxone Versus Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Mohamed, Adham, et al.
Publicado: (2020)

Penicillin-Susceptible Streptococcus pneumoniae Meningitis in Adults: Does the Ceftriaxone Dosing Matter?
por: Raemy, Samuel, et al.
Publicado: (2023)

In Vitro Susceptibility of Clinical Isolates to Ceftriaxone Alone and Ceftriaxone in Combination With Sulbactam or Tazobactam: A Comparative Study of Broad-Spectrum β-Lactam Antibiotics in India
por: Sanghavi, Sonali, et al.
Publicado: (2023)

85. The Impact of Carbapenem-Sparing Interventions on the Evolution of Resistance in Pseudomonas aeruginosa in the USA
por: Townsend, Jeffrey, et al.
Publicado: (2020)

Individual and community predictors of urinary ceftriaxone-resistant Escherichia coli isolates, Victoria, Australia
por: Chua, Kyra Y. L., et al.
Publicado: (2019)

Clinical and molecular characteristics of carbapenem non-susceptible Escherichia coli: A nationwide survey from Oman
por: Al-Farsi, Hissa M., et al.
Publicado: (2020)

Ceftriaxone-induced hemolysis
por: Guleria, Vivek S., et al.
Publicado: (2013)

Ceftriaxone‐associated pseudolithiasis
por: Kurihara, Masaru, et al.
Publicado: (2021)

1057. Treatment Efficacy of Ceftriaxone vs. Cefazolin for Methicillin-Susceptible Staphylococcus aureus Infections
por: Bhavan, Kavita, et al.
Publicado: (2018)

Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial
por: Harris, Patrick NA, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bjsafl00vkitpqqald6sg6vt60